GlassScriptPhysician profile
Kimberly Maynard
NPI 1063661635
$1,751.72
in general payments reported to CMS, 2019-2025
18 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $450 · 2022: $351 · 2023: $298 · 2024: $468 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $884 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $884.44 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $602.63 | 2021-2025 | |
| Novo Nordisk INC | $226.34 | 2021-2024 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $195.93 | 2023-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $112.93 | 2021-2025 | Airsupra |
| Lilly USA, LLC | $111.91 | 2021-2024 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $101.62 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $60.71 | 2021-2024 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $53.46 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $46.58 | 2021-2023 | Xarelto |
| Abbott Laboratories | $42.39 | 2024-2025 | Freestyle Libre 3 |
| Sunovion Pharmaceuticals INC. | $36.77 | 2021 | |
| Glaxosmithkline, LLC. | $32.86 | 2023-2024 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $29.13 | 2022-2024 | |
| Corium, LLC | $27.91 | 2024 | Azstarys |
| Pfizer INC. | $25.96 | 2022-2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $17.51 | 2025 | Watchman Flx |
| Merck Sharp & Dohme LLC | $15.05 | 2022 | |
| Supernus Pharmaceuticals, INC. | $12.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Maynard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.